ImmunityBio, Inc.

NASDAQ:IBRX

Biotechnology

Healthcare
$6.70 +2.58%

+$0.18 today

Market cap
$7.13B
Beta
0.10
P/E (TTM)
-8.6
EPS (TTM)
-$0.83
52W Low $1.95High $12.43

Volume 15.77M

Average 16.40M

IBRX EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

ImmunityBio, Inc.NASDAQ: IBRX

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA remains negative

Q3 FY2026 EBITDA was -$148.66M, compared with -$35.77M a year earlier. Trailing-twelve-month EBITDA was -$1.01B.

Context

  • EBITDA amounted to 197.3% of revenue in FY2025, down 1596.0 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of -$890.89M (-298.5%) for the fiscal year ending Dec 2026, a slowdown from the +15.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$148.66M+34.2% QoQ
Last fiscal yearDec 2025
-$223.56M+15.5% YoY
LTMSep 2026
-$1.01B-332.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-315.6%-261.1%+54.4 pp
1 year+15.5%-298.5%-314.0 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(223.56M) USD
Year-over-year change
+15.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How IBRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -332.3% is the 9th highest of 11, against a peer median of +20.4%.
  • EBITDA amounts to 550.8% of revenue for IBRX, versus a peer median of 42.2%.
IBRX Competitors
EBITDA for IBRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$99.55M USD+154.3%—7.3%
IMCRImmunocore Holdings plcLTM Mar 2026$6.24M USD+2711.1%—1.6%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026-$5.48M USD+4.6%—23.7%
NKTXNkarta, Inc.LTM Mar 2026-$90.7M USD+10.7%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$160.41M USD+32.7%——
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026-$185.11M USD+47.9%—48.8%
IMTXImmatics N.V.LTM Mar 2026-€202.4M EUR-4407.9%—542.7%
VIRVir Biotechnology, Inc.LTM Mar 2026-$438.52M USD+24.4%—669.6%
BNTXBioNTech SELTM Jun 2026-€941.06M EUR-2167.6%—35.6%
IBRXImmunityBio, Inc.LTM Sep 2026-$1.01B USD-332.3%—550.8%
MRNAModerna, Inc.LTM Sep 2026-$2.46B USD+16.4%—97.2%
Peer median (excluding IBRX) —+20.4%—42.2%

Competitors are the stored peer set for IBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue934K240K622K14.75M113.29M
Cost of Revenue0000753K
Gross Profit934K240K622K14.75M112.54M
Gross Margin100.0%100.0%100.0%100.0%99.3%
Research & Development195.96M248.15M232.37M190.14M207.88M
Selling, General & Admin135.26M102.71M129.62M168.78M147.18M
Operating Expenses331.21M351.54M362.87M358.93M368.56M
Depreciation & Amortization14.24M18.26M18.51M17.55M15.53M
EBITDA(320.75M)(351.88M)(478.66M)(264.43M)(223.56M)
EBITDA Margin-34341.8%-146617.1%-76955.5%-1793.4%-197.3%
Operating Income(330.28M)(351.3M)(362.25M)(344.18M)(256.03M)
Operating Margin-35361.9%-146374.2%-58239.5%-2334.2%-226.0%
Interest Income836K2.71M863K2.4M6.7M
Interest Expense14.85M47.15M86.72M131.66M112.53M
Other Income / Expenses(19.56M)(65.99M)(221.64M)(69.46M)(95.58M)
Income Before Tax(349.84M)(417.29M)(583.89M)(413.65M)(351.61M)
Pre-Tax Margin-37456.0%-173869.2%-93873.3%-2805.3%-310.4%
Income Tax Expense9K34K(40K)0(135K)
Net Income(346.79M)(416.57M)(583.2M)(413.56M)(351.4M)
Net Margin-37129.6%-173569.6%-93761.4%-2804.8%-310.2%
EPS (Basic)(0.89)(1.04)(1.15)(0.59)(0.38)
EPS (Diluted)(0.89)(1.04)(1.15)(0.62)(0.38)
Weighted Avg Shares389.23M399.9M508.64M697.31M919.86M
Weighted Avg Shares (Diluted)389.23M399.9M508.64M700.44M919.86M

ImmunityBio, Inc.

NASDAQ:IBRX

Intrinsic Alpha fair value

Locked

Current Price

$6.70

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.